http___www.kinderwunschklinik.de_hr_lijecenje_mogucnosti_lijecenja_limo_imunoterapija__1.xml
1.1 2.1 3.1 4.1 5.1 6.1 7.1 7.2 7.3 7.4 8.1 9.1 10.1 10.2 10.3
LIMO immunotherapy Intralipid immunomodulation for increasing the nidation rate - LIMO Studies on both animals and on humans have shown that intravenously administered Intralipid increases the nidation rate and thus can contribute towards sustaining a pregnancy. Intralipid is a 20% intravenous lipid emulsion, which is normally used as a provider of lipids and calories in patients who require parenteral nutrition . The emulsion is made up of 10% soya oil, 1.2% of egg yolk phospholipids, 2.25% of glycerine, and water. Intralipid stimulates the immune system to counteract “dangerous signs” that could lead to the loss of pregnancy (miscarriage). Intralipid does not contain any blood products, as would be the case with IVIG (= intravenous Immunoglobulin from blood plasma). Many women do not wish to undergo IVIG therapy because of a possible virus transmission. Furthermore, the costs of this kind of treatment are very high. Intralipid is free of such risks and only results in a tenth of the costs. It takes approximately 90 minutes to administer Intralipid intravenously. It is administered in the cycle prior to IVF, four to six days before the embryo transfer and in the case of a positive heartbeat of the baby. As soon as an intact preganancy is given (7th gestation week), treatment with Intralipid can be stopped. The compound displays hardly any side effects. Patients who would like to begin therapy with Intralipid may not have any allergies against soya or egg.
1.1 2.1 3.1 4.1 5.1 6.1 7.1 7.2 8.1 8.2 8.3 9.1 10.1 11.1 12.1 12.2
LIMO imunoterapija Intralipidna imunomodulacija u cilju povećavanja stope nidacije – LIMO Istraživanja kako na životinjama, tako i na ljudima pokazale su da intravenozno dani intralipid može povećati stopu nidacije, a time i doprinjeti održavanju trudnoće. Intralipid je 20% intravenozna emulzija masti, koja se obično koristi kao dobavljač masti i kalorija za pacijente kojima je potrebna parenteralna ishrana. Emulzija se sastoji 10% od soje, 1,2 % od žumanjka fosfolipida, 2,25% od glicerina i od vode. Intralipid stimulira imunosistem, kako bi se suzbili „opasni znaci“, koji bi mogli dovesti do gubitka trudnoće (pobačaja). Intralipid je relativno povoljan. Njegove prednosti za IVF pacijente s imunološkim smetnjama do sada su bile podcjenjene. Intralipid ne sadrži proizvode krvi, kao što bi to bio slučaj kod IVIG terapije (intravenoznog imunoglobulina). Mnoge žene ne žele se zbog mogućeg prijenosa virusa podvrgnuti IVIG terapiji, čiji su troškovi terapije veoma visoki. Intralipid je oslobođen ovih rizika i uz to iznosi samo desetinu troškova. Intralipid se pod nadzorom daje intravenozno i infuzija traje oko 90 minuta. Administracija se preporuča u predciklusu in vitro oplodnje, pri prijenosu zametka i pozitivnoj srčanoj reakciji djeteta. Odmah po nastupanju netaknute trudnoće (7.. tjedan), može se prestati s uzimanjem intralipida. Preparat ne bilježi neželjene reakcije. Pacijentice koje žele početi terapiju intralipidom ne smiju imati alergiju na soju ili jaja.